Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Forecast Expected deadline June 4, 2027 Opportunity RFA-CA-28-002

National Institutes of Health plans to offer grants of up to $300,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expects to make about 14 awards worth $6.6 million in total. It is a forecast: the notice is expected around January 15, 2027, with applications due around June 4, 2027.

From the official notice on Grants.gov, last changed July 14, 2026. Checked October 31, 2026.

Key dates

Forecast postedJuly 14, 2026
Expected postingJanuary 15, 2027
Expected deadlineJune 4, 2027
Expected award dateApril 1, 2028

Add the deadline to your calendar

Who can apply

This opportunity is open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development, enhancements, optimizations, and rigorous technical validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the clinical target or biological question being pursued are not appropriate for this solicitation. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Category: Health.

How to apply

  1. Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
  2. Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
  3. Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.

Questions go to IMAT Program Contact, NCI-IMAT@nih.gov, 240-255-0917.

Open the official notice

Questions people ask

Who can apply for Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)?

National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)?

Expected deadline June 4, 2027. Confirm the date and time in the official notice on Grants.gov.

How much funding is available?

Awards of up to $300,000 each. About $6.6 million in total across about 14 awards.

Similar open grants